Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 8/20 | 0.48 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
| ▸ | RXRA | P19793 | 6/20 | 0.38 |
| ▸ | NR1H3 | Q13133 | 6/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.38 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1677000 | 1.00 | NR1H2 (0.48) | NR1H2CHRNA7RXRANR1H3PTGS2 | |
| SCHEMBL1676032 | 0.90 | PTGS2 (0.43) | NR1H2RXRANR1H3PTGS2PTGS1 | |
| SCHEMBL1676034 | 0.90 | PTGS2 (0.43) | NR1H2RXRANR1H3PTGS2PTGS1 | |
| SCHEMBL1676670 | 0.87 | NR1H2 (0.48) | NR1H2CHRNA7RXRANR1H3PTGS2 | |
| SCHEMBL1676667 | 0.87 | NR1H2 (0.48) | NR1H2CHRNA7RXRANR1H3PTGS2 | |
| SCHEMBL1676459 | 0.84 | MAPT (0.39) | CHRNA7GABRA2GABRB2 | |
| SCHEMBL1676456 | 0.84 | MAPT (0.39) | CHRNA7GABRA2GABRB2 | |
| SCHEMBL1676847 | 0.77 | MAPT (0.40) | NR1H2CHRNA7PTGS2GABRA2GABRB2 | |
| SCHEMBL1676849 | 0.77 | MAPT (0.40) | NR1H2CHRNA7PTGS2GABRA2GABRB2 | |
| SCHEMBL1676065 | 0.76 | NR1H2 (0.44) | NR1H2RXRANR1H3PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110092553-A1 | Substituted Azole Derivatives, Compositions, and Methods of Use | TRANSTECH PHARMA, INC. (US) | 2011-04-21 | — | — | US | disclosed |
| EP-1730118-A1 | SUBSTITUTED AZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE | Transtech Pharma, Inc. (US) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005080346-A1 | SUBSTITUTED AZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE | TRANSTECH PHARMA, INC. (US) | 2005-09-01 | — | — | WO | disclosed |
| US-20050187277-A1 | Substituted azole derivatives, compositions, and methods of use | TRANSTECH PHARMA, INC. | 2005-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092553-A1 | Substituted Azole Derivatives, Compositions, and Methods of Use | PTPRO, PTPN5, PTPRE | NR1H2 2585/4885CHRNA7 4104/4885RXRA 2916/4885 |
| US-20050187277-A1 | Substituted azole derivatives, compositions, and methods of use | PTPRO, PTPN5, PTPRE | NR1H2 2585/4885CHRNA7 4104/4885RXRA 2916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.